Randomized study of BMS-986489 vs durvalumab in limited stage SCLC (TIGOS-LS)
Phase II/III Clinical Trial
An open-label randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)